Clinical trial
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de…
NCT00434148 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00434148 |
|---|---|
| Title | Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease |
| Official title | A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cushing's Disease |
| Intervention type | Drug |
| Interventions | Pasireotide |
| Enrollment | 162 |
| Start date | Dec 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | May 1, 2014 |
| First posted | Feb 12, 2007 |
| Last update posted | Mar 8, 2016 |
| Countries | Argentina, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Greece, Israel, Italy and 6 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: